In 2024, the global medical device industry revenue reached a new high,But the joys and sorrows of the giants are not connected.

Medtronic, Johnson & Johnson, AbbottWith sales exceeding $40 billion, they remain firmly in the first tier, but their growth dynamics are completely different — Johnson & Johnson's net profit declined due to the impact of centralized procurement, while Abbott's net profit surged thanks to innovative blood glucose meters and gains from the sale of its baby formula business.

Surgical robots become the biggest winner,Intuitive Surgical generated a net profit of $23.23 billion on sales of $83.52 billion.Net profit margin as high as 27.8%, far exceeding the industry average (12%)Its "equipment + consumables + services" closed-loop model accounts for 35% of new installations in the Chinese market, with annual consumable revenue per unit reaching $1.8 million.Philips' losses worsened due to the ventilator recall incident, and Baxter's hemodialysis machine prices halved in China, leading to a net loss.

Japanese companies Terumo and Olympus have maintained growth through disposable consumables,But China's centralized procurement policy has targeted high-margin sectors such as neurointervention, gradually intensifying the profit crisis in distribution channels...

Note: The fiscal year start dates for major companies differ from the calendar year, so there may be inconsistencies between fiscal quarters, fiscal years, and the natural year. Companies may announce their financial results on a quarterly or semi-annual basis.

Medtronic Announces Third Quarter Results Ended January 25, 2025Third-quarter net sales were $8.292 billion, compared to $8.089 billion in the same period last year. Operating profit for the quarter was $1.646 billion, compared to $1.483 billion in the same period last year. Net income attributable to the company for the quarter was $1.294 billion, compared to $1.322 billion in the same period last year.

Johnson & Johnson Announces Q4 and Full-Year 2024 ResultsJohnson & Johnson announced its financial results for the fourth quarter and full year of 2024. Fourth-quarter sales reached $22.52 billion, compared to $21.395 billion in the same period last year, representing a 5.3% year-over-year increase. Quarterly net profit was $3.431 billion, down 17% from $4.132 billion in the same period last year. Pharmaceutical business sales amounted to $14.332 billion, while medical device business sales reached $8.188 billion. Full-year sales totaled $88.821 billion, up 4.3% from $85.159 billion the previous year. Annual net profit was $14.066 billion, a 5.6% increase from $13.326 billion the previous year. Pharmaceutical business sales were $56.965 billion, and medical device business sales reached $31.857 billion.

Abbott Reports Fourth Quarter and Full-Year 2024 Results. Net sales for the quarter were $10.974 billion, compared to $10.241 billion in the same period last year. Quarterly net profit was $9.229 billion, compared to $1.594 billion in the same period last year. Excluding special items, quarterly net profit was $2.349 billion. By business segment, sales from the medical devices division were $5.052 billion, nutrition business sales were $2.129 billion, diagnostics business sales were $2.52 billion, and generic drug business sales were $1.268 billion. Full-year net sales were $41.95 billion, compared to $40.109 billion last year. Full-year net profit was $13.4 billion, compared to $5.723 billion last year. Excluding special items, full-year net profit was $8.2 billion.

Danaher Announces Q4 and Full-Year 2024 Results. Q4 revenue was $6.538 billion, compared to $6.405 billion in the same period last year. Operating profit for the quarter was $1.425 billion, compared to $1.337 billion last year. Net income attributable to common shareholders for the quarter was $1.086 billion, compared to $1.079 billion last year. Full-year revenue was $23.875 billion, compared to $23.89 billion the previous year. Full-year operating profit was $4.863 billion, compared to $5.202 billion the previous year. Full-year net income attributable to common shareholders was $3.899 billion, compared to $4.743 billion the previous year.

Medical device and equipment manufacturer Stryker announced its financial results for the fourth quarter and full year of 2024. Net sales for the fourth quarter were $6.436 billion, compared to $5.815 billion in the same period last year, representing a year-over-year increase of 10.7%. Operating profit for the quarter was $581 million, compared to $1.257 billion in the same period last year. Net profit for the quarter was $546 million, compared to $1.143 billion in the same period last year. For the full year, net sales were $22.595 billion, compared to $20.498 billion last year, an increase of 10.2% year-over-year. Full-year operating profit was $3.689 billion, compared to $3.888 billion last year. Full-year net profit was $2.993 billion, compared to $3.165 billion last year.

Siemens Healthineers Announces First Quarter Results for Fiscal Year Ending December 31, 2024Quarterly revenue reached €5.482 billion (approximately $5.695 billion), compared to €5.176 billion in the same period last year, representing a 5.9% year-over-year increase. Adjusted EBIT for the quarter was €822 million, up 11% from €747 million in the previous year. Quarterly net profit was €478 million, an 11% increase from €432 million in the same period last year.

GE HealthCare Reports Q4 and Full-Year 2024 Results. Total revenue for the fourth quarter was $5.319 billion, compared to $5.206 billion in the same period last year. Operating profit for the quarter was $801 million, compared to $689 million in the same period last year. Net income attributable to the company's ordinary shareholders for the quarter was $720 million, compared to $403 million in the same period last year. Total revenue for the full year was $19.672 billion, compared to $19.552 billion last year. Operating profit for the full year was $2.625 billion, compared to $2.435 billion last year. Net income attributable to the company's ordinary shareholders for the full year was $1.993 billion, compared to $1.385 billion last year.

Fresenius Medical Care Announces Q4 and Full-Year 2024 ResultsFresenius Medical Care announced its financial results for the fourth quarter and full year of 2024. Total revenue for the fourth quarter reached €5.085 billion (approximately $5.283 billion), compared to €4.988 billion in the same period last year. Operating profit for the quarter was €259 million, down from €428 million in the prior-year quarter. Net income attributable to shareholders of the company for the quarter was €67 million, compared to €188 million in the same period last year. For the full year, total revenue amounted to €19.336 billion, compared to €19.354 billion in the previous year. Annual operating profit was €1.392 billion, up from €1.369 billion the previous year. Net income attributable to shareholders of the company for the full year was €538 million, compared to €499 million in the previous year.

Philips Announces Q4 and Full-Year 2024 ResultsPhilips announced its financial results for the fourth quarter and full year of 2024. Fourth-quarter sales reached €5.044 billion (approximately $5.24 billion), compared to €5.062 billion in the same period last year. The company reported a net loss of €333 million for the quarter, compared to a net profit of €38 million in the previous year. Adjusted EBITDA for the quarter was €905 million, compared to €896 million in the same period last year. For the full year, total sales amounted to €18.021 billion, down from €18.169 billion the previous year. The company recorded a net loss of €698 million for the full year, compared to a net loss of €463 million in the prior year. Adjusted EBITDA for the full year stood at €2.982 billion, up from €2.845 billion in the previous year.

BD Reports First Fiscal Quarter Results for the Fiscal Year Ending December 31, 2024. Quarterly revenue was $5.168 billion, compared to $4.706 billion in the same period last year, representing a year-over-year increase of 9.8%. Quarterly operating profit was $453 million, compared to the same period last year.The amount for the period was $439 million. Quarterly net profit was $303 million, compared to $281 million in the same period last year.

Thermo Fisher Scientific Announces Q4 and Full-Year 2024 ResultsThermo Fisher Scientific reported its financial results for the fourth quarter and full year of 2024. Revenue for the fourth quarter was $11.395 billion, compared to $10.886 billion in the same period last year. Net income attributable to the company for the quarter was $1.83 billion, up from $1.63 billion in the prior-year period. Specifically, revenue from the life sciences business was $2.604 billion, laboratory products and biopharma services revenue was $5.936 billion, specialty diagnostics revenue was $1.157 billion, and analytical instruments revenue was $2.186 billion. Full-year revenue was $42.879 billion, compared to $42.857 billion last year. Full-year net income attributable to the company was $6.335 billion, up from $5.995 billion the previous year.

Boston Scientific Announces Q4 and Full-Year 2024 ResultsQ4 net sales were $4.561 billion, compared to $3.725 billion in the same period last year. Operating profit for the quarter was $676 million, compared to $584 million in the same period last year. Net income attributable to common shareholders for the quarter was $566 million, compared to $504 million in the same period last year. Full-year net sales were $16.747 billion, compared to $14.22 billion last year. Full-year operating profit was $2.603 billion, compared to $2.343 billion last year. Full-year net income attributable to common shareholders was $1.853 billion, compared to $1.57 billion last year.

Roche Announces 2024 Financial Results. The group's total annual sales were 60.495 billion Swiss francs, compared to 58.716 billion Swiss francs in the previous year, representing a year-on-year increase of 3%. The group’s annual operating profit was 13.417 billion Swiss francs, down from 15.395 billion Swiss francs the previous year, marking a year-on-year decrease of 13%. The net profit attributable to shareholders for the full year was 8.277 billion Swiss francs, compared to 11.498 billion Swiss francs the previous year, representing a year-on-year decrease of 28%. Specifically, the pharmaceuticals division reported annual sales of 46.171 billion Swiss francs and an operating profit of 15.587 billion Swiss francs. The diagnostics division reported annual sales of 14.324 billion Swiss francs (approximately 15.9 billion US dollars) and an operating profit of 1.946 billion Swiss francs.

Henry Schein Announces Fourth Quarter and Full Year 2024 Results. Fourth quarter net sales were $3.191 billion, compared to $3.017 billion in the same period last year. Quarterly operating profit was $155 million, compared to $39 million in the same period last year. Quarterly net profit attributable to the company was $94 million, compared to $18 million in the same period last year. Full year net sales were $12.673 billion, compared to $12.339 billion last year. Full year operating profit was $621 million, compared to $615 million last year. Full year net profit attributable to the company was $390 million, compared to $416 million last year.

Cardinal Health Reports Second Quarter Fiscal 2025 Results Ended December 31, 2024. Quarterly revenue was $55.264 billion, compared to $57.442 billion in the same period last year. Net income attributable to the company for the quarter was $400 million, compared to $368 million in the same period last year. Among this, revenue from medical products and distribution business was $3.2 billion, compared to $3.1 billion in the same period last year; quarterly profit was $18 million, compared to $11 million in the same period last year.

Baxter International announced its financial results for the fourth quarter and full year of 2024. The net sales in the fourth quarter were $2.753 billion, compared to $2.729 billion in the same period last year. The operating loss for the quarter was $435 million, while the profit was $304 million in the same period last year. The net loss attributable to shareholders for the quarter was $512 million, compared to a net profit of $245 million in the same period last year. The full-year net sales amounted to $10.636 billion, compared to $10.36 billion the previous year. The annual operating profit was $14 million, down from $707 million the previous year. The net loss attributable to shareholders for the full year was $649 million, compared to a net profit of $2.656 billion the previous year.

Owens & Minor Announces Fourth Quarter and Full Year 2024 Results. Fourth quarter revenue was $2.696 billion, compared to $2.656 billion in the same period last year. The quarter's operating loss was $262 million, compared to an operating profit of $60 million in the same period last year. Net loss for the quarter was $296 million, compared to a net profit of $18 million in the same period last year. Full-year revenue was $10.701 billion, compared to $10.334 billion last year. Full-year operating loss was $208 million, compared to an operating profit of $105 million last year. Full-year net loss was $363 million, compared to a net loss of $41 million last year.

Intuitive Surgical Announces Q4 and Full-Year 2024 Results. Total revenue for the fourth quarter was $2.414 billion, compared to $1.928 billion in the same period last year. Quarterly operating profit was $735 million, compared to $450 million in the same period last year. Quarterly net profit attributable to the company was $686 million, compared to $606 million in the same period last year. Full-year total revenue was $8.352 billion, compared to $7.124 billion last year. Full-year operating profit was $2.349 billion, compared to $1.767 billion last year. Full-year net profit attributable to the company was $2.323 billion, compared to $1.798 billion last year.

Solventum (formerly 3M Health Care Business) Announces Q4 and Full-Year 2024 Results. Total net sales for Q4 were $2.074 billion, compared to $2.036 billion in the same period last year. Operating profit for the quarter was $136 million, compared to $406 million in the prior-year quarter. Net profit for the quarter was $30 million, compared to $272 million in the same period last year. Total net sales for the full year were $8.254 billion, compared to $8.197 billion the previous year. Annual operating profit was $1.036 billion, compared to $1.692 billion the previous year. Annual net profit was $479 million, compared to $1.346 billion the previous year.

Zimmer Biomet Holdings Announces Q4 and Full-Year 2024 ResultsQ4 net sales were $2.023 billion, compared to $1.94 billion in the same period last year. Quarterly operating profit was $389 million, compared to $354 million in the same period last year. Quarterly net profit attributable to the company was $239 million, compared to $419 million in the same period last year. Full-year net sales were $7.679 billion, compared to $7.394 billion last year. Full-year operating profit was $1.286 billion, compared to $1.278 billion last year. Full-year net profit attributable to the company was $904 million, compared to $1.024 billion last year.

Terumo Reports Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2024. Revenue for the period was 772.235 billion yen (approximately 5.153 billion USD), compared to 682.951 billion yen in the same period last year, representing a year-on-year increase of 13.1%. Operating profit for the period was 133.496 billion yen, compared to 105.519 billion yen in the same period last year, marking a year-on-year increase of 26.5%. Net profit attributable to owners of the parent company for the period was 98.622 billion yen, compared to 79.897 billion yen in the same period last year, reflecting a year-on-year increase of 23.4%.

Olympus (OLYMPUS) Announces Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2024. Revenue for the period was 725.221 billion yen (approximately 4.839 billion USD), compared to 668.097 billion yen in the same period last year, representing an 8.6% year-over-year increase. Operating profit for the period was 108.795 billion yen, compared to 37.985 billion yen in the same period last year, marking a 186.4% year-over-year increase. Net profit attributable to owners of the parent company for the period was 76.384 billion yen, compared to 235.212 billion yen in the same period last year, reflecting a 67.5% year-over-year decrease.。

Canon Group Releases Q4 and Full-Year 2024 Financial Results. In Q4, the group's net sales reached 1,273.71 billion yen, with an operating loss of 16.884 billion yen and a net loss attributable to the company of 58.544 billion yen. In the printing business, net sales were 677.07 billion yen; in the medical business, net sales were 161.271 billion yen (approximately 1.076 billion USD); in the imaging business, net sales were 277.552 billion yen; and in the industrial business, net sales were 122.248 billion yen. For the full year, the group’s net sales totaled 4,509.821 billion yen, a year-on-year increase of 7.9%. The annual operating profit was 279.754 billion yen, a year-on-year decrease of 25.5%. The net profit attributable to the company for the year was 160.025 billion yen, a year-on-year decrease of 39.5%.

Fujifilm Holdings Releases Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2024. During this period, the group's sales revenue increased by 8% year-on-year, reaching 2,327.5 billion yen. Operating profit reached 223.3 billion yen, a year-on-year increase of 9%, and net profit attributable to the group increased by 4.5% year-on-year, reaching 181.5 billion yen. In each business segment, healthcare business revenue increased by 3.2% year-on-year, reaching 712.6 billion yen (approximately 4.756 billion US dollars). Electronic materials business revenue increased by 27.5% year-on-year, reaching 326.2 billion yen. Imaging business revenue increased by 15.8% year-on-year, reaching 426.7 billion yen. Business innovation revenue increased by 2.6% year-on-year, reaching 862 billion yen.

Ophthalmology

EssilorLuxottica Reports Q4 and Full-Year 2024 Results. Total revenue for Q4 reached €6.781 billion, compared to €6.25 billion in the same period last year. Revenue from professional solutions amounted to €3.117 billion (approximately $3.238 billion), up from €2.986 billion the previous year. Consumer business revenue was €3.664 billion, compared to €3.264 billion in the prior year. Total revenue for the full year was €26.508 billion, an increase from €25.395 billion the previous year. Annual operating profit was €4.414 billion, compared to €4.178 billion the prior year. Net profit for the year was €3.122 billion, up from €2.946 billion the previous year.

Alcon Announces Q4 and Full-Year 2024 Results. Net sales and other revenue for Q4 reached $2.502 billion, compared to $2.352 billion in the same period last year. Operating profit for the quarter was $395 million, up from $208 million the previous year. Quarterly net profit was $284 million, compared to $427 million in the same period last year. For the full year, net sales and other revenue totaled $9.911 billion, compared to $9.455 billion the previous year. Annual operating profit was $1.413 billion, up from $1.039 billion the prior year. Full-year net profit was $1.018 billion, compared to $974 million the previous year.

Bausch+Lomb Reports Fourth Quarter and Full Year 2024 Results. Fourth quarter revenue was $1.28 billion, compared to $1.173 billion in the same period last year. Quarterly operating profit was $87 million, compared to $49 million in the same period last year. Net loss attributable to the company for the quarter was $3 million, compared to a net loss of $54 million in the same period last year. Full-year revenue was $4.791 billion, compared to $4.146 billion last year. Annual operating profit was $162 million, compared to $130 million last year. Net loss attributable to the company for the full year was $317 million, compared to a net loss of $260 million last year.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

 

Single Product Sales Surpass 1 Billion in China, Hidden Leader Medtronic Cuts 10% of Workforce

ECR 2025 Grand Overview: GPS, Canon...

Olympus, Global Level 1 Recall

143-Year-Old Medical Device Giant Considers Selling Key Business

The Power of China at ECR 2025: United Imaging, Mindray, Neusoft...

Surgical Giant Splits in Two, Stock Price Drops 21.76%

What New Possibilities Will Song Weiqun Bring to GE Healthcare as He Takes Over from Zhang Yihao?

"Universal Pharmacy" Shuts Down Acquisition of Device Business

The King of Hemodialysis: 8,200 Employees Already Laid Off

CEO of Radiation Therapy Giant Resigns

BusinessBusiness cooperation email: qxzj@landianyiliao.com